These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 15154741)
1. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Hagenbeek A Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741 [TBL] [Abstract][Full Text] [Related]
2. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Witzig TE Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375 [TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
5. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924 [TBL] [Abstract][Full Text] [Related]
6. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Marcus R Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024 [TBL] [Abstract][Full Text] [Related]
7. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209 [TBL] [Abstract][Full Text] [Related]
8. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Witzig TE Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033 [TBL] [Abstract][Full Text] [Related]
9. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300 [TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399 [TBL] [Abstract][Full Text] [Related]
11. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Wiseman GA; Gordon LI; Multani PS; Witzig TE; Spies S; Bartlett NL; Schilder RJ; Murray JL; Saleh M; Allen RS; Grillo-López AJ; White CA Blood; 2002 Jun; 99(12):4336-42. PubMed ID: 12036859 [TBL] [Abstract][Full Text] [Related]
12. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy. Clayton J Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742 [TBL] [Abstract][Full Text] [Related]
13. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814 [TBL] [Abstract][Full Text] [Related]
14. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572 [TBL] [Abstract][Full Text] [Related]
15. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Emmanouilides C; Witzig TE; Gordon LI; Vo K; Wiseman GA; Flinn IW; Darif M; Schilder RJ; Molina A Leuk Lymphoma; 2006 Apr; 47(4):629-36. PubMed ID: 16690521 [TBL] [Abstract][Full Text] [Related]
16. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Nademanee A; Forman S; Molina A; Fung H; Smith D; Dagis A; Kwok C; Yamauchi D; Anderson AL; Falk P; Krishnan A; Kirschbaum M; Kogut N; Nakamura R; O'donnell M; Parker P; Popplewell L; Pullarkat V; Rodriguez R; Sahebi F; Smith E; Snyder D; Stein A; Spielberger R; Zain J; White C; Raubitschek A Blood; 2005 Oct; 106(8):2896-902. PubMed ID: 16002426 [TBL] [Abstract][Full Text] [Related]
17. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. Cheson BD BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072 [TBL] [Abstract][Full Text] [Related]
18. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962 [TBL] [Abstract][Full Text] [Related]
20. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL). Bischof Delaloye A Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]